Middle East Genome Editing Market To Reach $668.6 Million By 2033

August 2025 | Report Format: Electronic (PDF)

Middle East Genome Editing Market Growth & Trends

The Middle East genome editing market size is projected to reach USD 668.6 million by 2033, growing at a CAGR of 9.78% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is experiencing rapid growth, driven by rising investment in precision medicine, advanced therapeutics, and agricultural biotechnology.

The region’s high prevalence of genetic disorders such as sickle cell anemia, beta-thalassemia, and other inherited metabolic diseases creates a pressing need for innovative treatment approaches, boosting demand for cutting-edge genome editing platforms like CRISPR-Cas9, TALENs, and base editors. Government-backed genomic initiatives, including large-scale population sequencing programs in Saudi Arabia, Qatar, and the UAE, foster a strong research, innovation, and clinical translation ecosystem. Supportive regulatory developments and targeted funding for biotechnology R&D are accelerating adoption and expanding the scope of applications.

Strong research infrastructure, expanding clinical capabilities, and increasing collaboration between academic institutions, healthcare providers, and global biotech companies propel the market forward. These partnerships translate laboratory breakthroughs into viable therapeutic solutions, with momentum in rare disease gene therapies, regenerative medicine, and personalized oncology.

Technological advancements in delivery mechanisms, target specificity, and off-target risk reduction are broadening the therapeutic landscape, while integration with AI-powered bioinformatics is optimizing target selection and workflow efficiency. Beyond healthcare, genome editing is applied to develop drought-resistant, high-yield crops and improve livestock genetics, aligning with regional food security and sustainability priorities. With cross-sector alliances, active technology transfer, and a growing talent base, the Middle East is emerging as a dynamic hub for genome editing innovation, positioned to play a pivotal role in both therapeutic and non-therapeutic applications globally.

key Request a free sample copy or view report summary: Middle East Genome Editing Market Report

Middle East Genome Editing Market Report Highlights

By technology, CRISPR/Cas9 dominated the Middle East genome editing industry in 2024, accounting for the largest revenue share of 46.83%. Its leadership stems from CRISPR/Cas9's unmatched efficiency, precision, and relatively low cost, making it the preferred platform for targeted genome modifications. Technology’s adoption spans the region's medical research centers, universities, biotech startups, and agricultural R&D hubs. Its ease of design, scalability, and applicability to both in vitro and in vivo workflows have made CRISPR/Cas9 central to functional genomics studies, rare disease therapy development, and climate-resilient crop engineering, strategically important for Middle Eastern economies.
By delivery method, in vivo genome editing led the market in 2024, driven by expanding investments in advanced therapies for inherited genetic disorders and oncology. The region's push toward precision medicine, supported by initiatives like the Saudi Human Genome Program and Abu Dhabi's introduction of CRISPR-based therapies, has accelerated the development and adoption of novel delivery platforms, including lipid nanoparticles and adeno-associated viral vectors (AAVs). Direct genetic modification within patients is increasingly viewed as a transformative healthcare approach, attracting multinational partnerships, clinical trial activity, and regulatory interest.
By application, genetic engineering emerged as the leading segment in 2024, contributing the highest revenue share. This dominance is fueled by extensive use in disease modeling, drug discovery, and agricultural biotechnology. Academic and commercial research entities across the Middle East are leveraging genetic engineering to create custom cell lines, engineer disease-resistant crops, and develop livestock with improved productivity.
By mode, the contract segment held the largest share in 2024, reflecting the growing trend of outsourcing genome editing projects to specialized service providers. Many regional research institutions and early-stage biotech companies rely on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) for access to advanced genome editing tools, biosafety infrastructure, and regulatory compliance expertise. This outsourcing model accelerates time-to-market for new therapies and reduces capital expenditure, particularly for smaller innovators.
By end use, biotechnology and pharmaceutical companies dominated the Middle East genome editing industry with a revenue share of50.36% in 2024. These players drive innovation by integrating genome editing into therapeutic pipelines for rare genetic diseases, regenerative medicine, and oncology. With growing R&D budgets, government-backed incentives, and collaborations with leading academic institutions and global biotech firms, these companies are at the forefront of translating genome editing breakthroughs into clinical and commercial products. Their leadership role is reinforced by the region's strategic investments in biotech clusters and innovation hubs, ensuring sustained market growth across both healthcare and agricultural applications.

Middle East Genome Editing Market Segmentation

Grand View Research has segmented the Middle East genome editing market based on technology, delivery method, application, mode, end use, and country:

Middle East Genome Editing Technology Outlook (Revenue, USD Million, 2021 - 2033)

(CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Meganucleases
Others

Middle East Genome Editing Delivery Method Outlook (Revenue, USD Million, 2021 - 2033)

Ex vivo
In vivo

Middle East Genome Editing Application Outlook (Revenue, USD Million, 2021 - 2033)

Genetic Engineering
- Cell line engineering
- Animal genetic engineering
- Plant genetic engineering
- Others
Clinical Applications
- Diagnostics Development
- Therapy Development